We examined the peroxisome proliferator-activated receptor (PPARG) locus in an attempt to identify expressed sequence tags and/or conserved non-coding sequences in the intron sequences containing open reading frames and potentially able to encode new proteins. We identified a new PPARG transcript, defined ORF4, which harbors a readthrough in intron 4. The expected translated protein lacks the ligand-binding domain encoded by exons 5 and 6. We identified the transcript in human tumor cell lines and tissues, synthesized the cDNA, and cloned it in expression vectors. Using transient transfections, we found that ORF4 cDNA is translated into a predominantly nuclear protein that does not transactivate a reporter gene. Moreover, the isoform is dominant negative versus PPAR. Interestingly, ORF4 was expressed in vivo in a series of sporadic colorectal cancers. In some cases, it was expressed, albeit at lower levels, also in the mucosa adjacent to the tumors, suggesting that it may be related to tumorigenesis. A tumorigenic effect of ORF4 is in line with our finding that ORF4 has not only lost the capacity to restrain cell growth but has acquired the potential to stimulate it. In conclusion, this study demonstrates that ORF4 is expressed in vivo, that it has lost some PPAR properties, and that it affects PPAR functioning. The ability to counteract PPAR suggests that ORF4 plays a role in the pathogenesis of colorectal cancers
A novel peroxisome proliferator-activated receptor gamma isoform with dominant negative activity generated by alternative splicing
SABATINO L;COLANTUONI V
2005-01-01
Abstract
We examined the peroxisome proliferator-activated receptor (PPARG) locus in an attempt to identify expressed sequence tags and/or conserved non-coding sequences in the intron sequences containing open reading frames and potentially able to encode new proteins. We identified a new PPARG transcript, defined ORF4, which harbors a readthrough in intron 4. The expected translated protein lacks the ligand-binding domain encoded by exons 5 and 6. We identified the transcript in human tumor cell lines and tissues, synthesized the cDNA, and cloned it in expression vectors. Using transient transfections, we found that ORF4 cDNA is translated into a predominantly nuclear protein that does not transactivate a reporter gene. Moreover, the isoform is dominant negative versus PPAR. Interestingly, ORF4 was expressed in vivo in a series of sporadic colorectal cancers. In some cases, it was expressed, albeit at lower levels, also in the mucosa adjacent to the tumors, suggesting that it may be related to tumorigenesis. A tumorigenic effect of ORF4 is in line with our finding that ORF4 has not only lost the capacity to restrain cell growth but has acquired the potential to stimulate it. In conclusion, this study demonstrates that ORF4 is expressed in vivo, that it has lost some PPAR properties, and that it affects PPAR functioning. The ability to counteract PPAR suggests that ORF4 plays a role in the pathogenesis of colorectal cancersFile | Dimensione | Formato | |
---|---|---|---|
JBC Sabatino .pdf
non disponibili
Licenza:
Non specificato
Dimensione
310.62 kB
Formato
Adobe PDF
|
310.62 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.